Quantcast
Channel: Proactiveinvestors Australia
Viewing all articles
Browse latest Browse all 12

Pivotal Therapeutics appoints cardiology veteran to its board of directors

0
0

Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO) has appointed Dr. John P. Nicholson Jr., a cardiologist and clinical associate professor of medicine at Cornell University, to the company's board of directors, as it continues to accelerate the commercialization of its Omega-3 therapy for cardiovascular disease. 

Dr. Nicholson is also currently the medical director of the Cardiac Health Center, a cardiac rehab program at New York Hospital in Queens. He has more than 30 years of experience as a healthcare and life sciences investor, analyst and portfolio manager, according to Pivotal's statement. 

He was the founder and portfolio manager of Sands Point Partners, and was also a portfolio manager at Steinhardt Partners and a consultant at Tiger Management, along with director of healthcare investment banking at the Bank Street Group. 

Dr. Nicholson is also the director of research at Crossover Healthcare Fund, a significant shareholder in Pivotal. 

“We are pleased to welcome Dr. Nicholson to the Board of Directors of Pivotal Therapeutics. Dr. Nicholson’s medical and investment expertise make him an exceptional addition to the Board at this stage of the company’s development," said co-founder and chairman, Dr. George Jackowski, as Pivotal explores various strategic initiatives with its product and enters into its next stage of growth.

"We look forward to his input as a leading edge Cardiologist as we continue to study the clinical effects of VASCAZEN in cardiac rehabilitation, obesity, metabolic syndrome and heart failure."

The specialty pharmaceutical company is working to fully commercialize its Vascazen FDA-regulated medical food product, which was developed to lower cardiovascular health risks in Omega-3 deficient cardiac patients. This includes high triglycerides, or fatty substances in the blood that are associated with coronary disease. The product is available with a prescription in all major pharmacies throughout the U.S.

Currently, the company's sales reps are focused on marketing the product on the eastern seaboard in the U.S., which it says contains the highest prevalence of cardiovascular disease-related illness in the nation. The 90 percent-pure Omega-3 product, which was introduced in the U.S. in November 2011, provides those suffering from heart disease with levels of the most important Omega-3 fatty acids in fish oil – EPA and DHA – that the company says are ideal, and cannot be achieved just through simple changes in diet alone.

“As a cardiologist we see numerous drugs that aim to treat cardiovascular diseases and symptoms of underlying cardiovascular disease. I am excited that a company is exploring Omega-3 deficiency, its affects and addressing Omega-3 deficiency in a novel way, through utilization of a Medical Food that corrects the underlying deficiency itself," said Dr. Nicholson in a statement announcing his appointment. 


Viewing all articles
Browse latest Browse all 12

Latest Images

Trending Articles





Latest Images